The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas
Top Cited Papers
- 1 August 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 39 (6) , 799-800
- https://doi.org/10.1097/mpa.0b013e3181ebb56f
Abstract
Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate. These high-grade malignancies are characterized by aggressive histological features (high mitotic rate, extensive necrosis, and nuclear atypia) and a poor clinical prognosis. They are infrequently associated with secretory hormonal syndromes (such as the carcinoid syndrome) and rarely express somatostatin receptors. Most poorly differentiated neuroendocrine carcinomas are locally advanced or metastatic at presentation. First-line systemic chemotherapy with a platinum agent (cisplatin or carboplatin) and etoposide is recommended for most patients with metastatic-stage disease; however, response durations are often short. Sequential or concurrent chemoradiation is recommended for patients with loco-regional disease. In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted in most cases.Keywords
This publication has 17 references indexed in Scilit:
- Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumorsHuman Pathology, 2009
- Clinical and therapeutic aspects of extrapulmonary small cell carcinomaCancer Treatment Reviews, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?The American Journal of Surgical Pathology, 2008
- Extrapulmonary small‐cell carcinoma compared with small‐cell lung carcinomaCancer, 2007
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow upAnnals of Oncology, 1996
- Pathology and Nomenclature of Human Gastrointestinal Neuroendocrine (Carcinoid) Tumors and Related LesionsWorld Journal of Surgery, 1996
- Revised classification of neuroendocrine tumours of the lung, pancreas and gutVirchows Archiv, 1995